Cargando…
How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency
Congenital factor XIII (FXIII) deficiency is an extremely rare bleeding disorder (RBD) with estimated prevalence of one per 2 million in the general population. The disorder causes different clinical manifestations such as intracranial hemorrhage (ICH), recurrent miscarriage, umbilical cord bleeding...
Autores principales: | Shahraki, Hojat, Dorgalaleh, Akbar, Fathi, Majid, Tabibian, Shadi, Teimourian, Shahram, Mollanoori, Hasan, khiabani, Alireza, Zaker, Farhad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876424/ https://www.ncbi.nlm.nih.gov/pubmed/33603988 http://dx.doi.org/10.18502/ijhoscr.v14i4.4480 |
Ejemplares similares
-
Current understanding in diagnosis and management of factor XIII deficiency
por: Naderi, M, et al.
Publicado: (2013) -
Inhibitor in Congenital Factor VII Deficiency; a Rare but Serious Therapeutic Challenge—A Systematic Literature Review
por: Ramezanpour, Nahid, et al.
Publicado: (2021) -
Public Health Problems related to factor V deficiency in southeast of Iran
por: Naderi, Majid, et al.
Publicado: (2014) -
Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®
por: Naderi, Majid, et al.
Publicado: (2016) -
Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
por: Mollanoori, Hasan, et al.
Publicado: (2020)